{"id":1036466,"date":"2012-08-30T02:13:33","date_gmt":"2012-08-30T02:13:33","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/puma-biotechnology-to-present-at-stifel-nicolaus-2012-healthcare-conference.php"},"modified":"2024-08-17T15:56:39","modified_gmt":"2024-08-17T19:56:39","slug":"puma-biotechnology-to-present-at-stifel-nicolaus-2012-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/puma-biotechnology-to-present-at-stifel-nicolaus-2012-healthcare-conference.php","title":{"rendered":"Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference"},"content":{"rendered":"<p><p>      LOS ANGELES--(BUSINESS WIRE)--    <\/p>\n<p>      Puma Biotechnology, Inc. (PBYI),      a development stage biopharmaceutical company, announced that      Alan H. Auerbach, Chairman, Chief Executive Officer,      President and Founder of Puma, will present an overview of      the Company at 11:30 a.m. EDT on Wednesday, September 5, at      the Stifel Nicolaus 2012 Healthcare Conference in Boston.    <\/p>\n<p>      A live webcast will be available on the Companys website at            <a href=\"http:\/\/www.pumabiotechnology.com\" rel=\"nofollow\">http:\/\/www.pumabiotechnology.com<\/a>. The presentation will be      archived on the website and available for 30 days.    <\/p>\n<p>      About Puma Biotechnology    <\/p>\n<p>      Puma Biotechnology, Inc. is a development stage      biopharmaceutical company that acquires and develops      innovative products for the treatment of various forms of      cancer. The Company focuses on in-licensing drug candidates      that are undergoing or have already completed initial      clinical testing for the treatment of cancer and then seeks      to further develop those drug candidates for commercial use.      The Company is initially focused on the development of PB272      (oral neratinib), a potent irreversible tyrosine kinase      inhibitor, for the treatment of patients with HER2 positive      metastatic breast cancer.    <\/p>\n<p>      Further information about Puma Biotechnology can be found at            <a href=\"http:\/\/www.pumabiotechnology.com\" rel=\"nofollow\">http:\/\/www.pumabiotechnology.com<\/a>.    <\/p>\n<p>      Forward-Looking Statements:    <\/p>\n<p>      This press release contains forward-looking statements that      involve risks and uncertainties that could cause the      Company's actual results to differ materially from the      anticipated results and expectations expressed in these      forward-looking statements. These statements are based on      current expectations, forecasts and assumptions, and actual      outcomes and results could differ materially from these      statements due to a number of factors, which include, but are      not limited to, the risk factors disclosed in the periodic      reports filed by the Company with the Securities and Exchange      Commission from time to time. Readers are cautioned not to      place undue reliance on these forward-looking statements,      which speak only as of the date hereof. The Company assumes      no obligation to update these forward-looking statements,      except as required by law.    <\/p>\n<\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/puma-biotechnology-present-stifel-nicolaus-123000076.html;_ylt=A2KJjalBzD5QTBcA.1T_wgt.\" title=\"Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference\" rel=\"noopener\">Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:30 a.m.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/puma-biotechnology-to-present-at-stifel-nicolaus-2012-healthcare-conference.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036466","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036466"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036466"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036466\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}